BioSpace News Archive

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet needs, provided a corporate update.

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for Dupixent® Medical to treat adults with prurigo nodularis, a chronic skin disease that causes extreme itch and inflammatory skin lesions.

Selvita S.A., one of the largest preclinical contract research organizations in Europe, continues its development in all business segments in the first quarter of 2022.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, and Takeda have announced the transfer of the marketing authorization for Moderna’s COVID-19 vaccine SpikevaxTM from Takeda to Moderna in Japan as of August 1, 2022.

To help people living with asthma and save lives, the American Lung Association and other leading asthma experts with support from the Centers for Disease Control and Prevention ‘s National Center for Environmental Health, will release the National Asthma Public Policy Agenda on June 1.

Quebec-based AMD Medicom Inc., one of the world’s leading manufacturers and distributors of personal protective equipment, is excited to announce a new partnership with Vitacore Industries Inc., a British Columbia-based company that manufactures surgical masks and respirators.

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers, announced that Cuong Do, a longtime industry veteran has joined the Seneca Therapeutics Advisory Board.

BioAge Labs, Inc. announced that Kristen Fortney, PhD, CEO and Co-Founder of BioAge, will lead a panel discussion at the BIO International Conference held June 13–16, 2022 in San Diego, California.

Zealand Pharma Announces Multiple Presentations at the 82nd Annual American Diabetes Association Scientific Sessions, Including Initial Clinical Data on GLP-1/GLP-2 Dual Agonist Dapiglutide.

Matinas BioPharma announced today that Jerry Jabbour, Chief Executive Officer, has been invited to present at the LD Micro Invitational XII Conference on Tuesday, June 7, 2022, at 3:30 p.m. ET (12:30 p.m. PT).